scholarly journals A case of chronic postural tachycardia syndrome with positive anti-ganglionic acetylcholine receptor (gAChR) antibody

Author(s):  
Yuya Goto ◽  
Yoko Sunami ◽  
Keizo Sugaya ◽  
Shunya Nakane ◽  
Kazushi Takahashi
2014 ◽  
Vol 36 (1) ◽  
pp. 165-170 ◽  
Author(s):  
Jiawei Li ◽  
Qingyou Zhang ◽  
Ying Liao ◽  
Chunyu Zhang ◽  
Hongjun Hao ◽  
...  

2021 ◽  
Vol 11 (4) ◽  
pp. e397-e401
Author(s):  
Meredith Bryarly ◽  
Satish R. Raj ◽  
Lauren Phillips ◽  
Linda S. Hynan ◽  
Luis E. Okamoto ◽  
...  

ObjectivePostural tachycardia syndrome (POTS), the most common form of dysautonomia, may be associated with autoimmunity in some cases. Autoantibodies against the ganglionic acetylcholine receptor (gAChR) have been reported in a minority of patients with POTS, but the prevalence and clinical relevance is unclear.MethodsClinical information and serum samples were systematically collected from participants with POTS and healthy control volunteers (n = 294). The level of positive gAChR antibodies was classified as very low (0.02–0.05 nmol/L), low (0.05–0.2 nmol/L), and high (>0.2 nmol/L).ResultsFifteen of 217 patients with POTS (7%) had gAChR antibodies (8 very low and 7 low). Six of the 77 healthy controls (8%) were positive (3 very low and 3 low). There were no clinical differences between seropositive and seronegative patients with POTS.ConclusionsPrevalence of gAChR antibody did not differ between POTS and healthy controls, and none had high antibody levels. Patients with POTS were not clinically different based on seropositivity. Low levels of gAChR antibodies are not clinically important in POTS.


2019 ◽  
Vol 286 (4) ◽  
pp. 438-448 ◽  
Author(s):  
B. H. Shaw ◽  
L. E. Stiles ◽  
K. Bourne ◽  
E. A. Green ◽  
C. A. Shibao ◽  
...  

2021 ◽  
Vol 77 (17) ◽  
pp. 2174-2184 ◽  
Author(s):  
Emily M. Garland ◽  
Alfredo Gamboa ◽  
Victor C. Nwazue ◽  
Jorge E. Celedonio ◽  
Sachin Y. Paranjape ◽  
...  

2007 ◽  
Vol 135 (1-2) ◽  
pp. 151-152
Author(s):  
Naotoshi Tamura ◽  
Toshimasa Yamamoto ◽  
Yoshihiko Nakazato ◽  
Kaori Itokawa ◽  
Kunio Shimazu

Author(s):  
Alex Buoite Stella ◽  
Giovanni Furlanis ◽  
Nicolò Arjuna Frezza ◽  
Romina Valentinotti ◽  
Milos Ajcevic ◽  
...  

AbstractThe autonomic nervous system (ANS) can be affected by COVID-19, and dysautonomia may be a possible complication in post-COVID individuals. Orthostatic hypotension (OH) and postural tachycardia syndrome (POTS) have been suggested to be common after SARS-CoV-2 infection, but other components of ANS function may be also impaired. The Composite Autonomic Symptom Scale 31 (COMPASS-31) questionnaire is a simple and validated tool to assess dysautonomic symptoms. The aim of the present study was to administer the COMPASS-31 questionnaire to a sample of post-COVID patients with and without neurological complaints. Participants were recruited among the post-COVID ambulatory services for follow-up evaluation between 4 weeks and 9 months from COVID-19 symptoms onset. Participants were asked to complete the COMPASS-31 questionnaire referring to the period after COVID-19 disease. Heart rate and blood pressure were manually taken during an active stand test for OH and POTS diagnosis. One-hundred and eighty participants were included in the analysis (70.6% females, 51 ± 13 years), and OH was found in 13.8% of the subjects. Median COMPASS-31 score was 17.6 (6.9–31.4), with the most affected domains being orthostatic intolerance, sudomotor, gastrointestinal and pupillomotor dysfunction. A higher COMPASS-31 score was found in those with neurological symptoms (p < 0.01), due to more severe orthostatic intolerance symptoms (p < 0.01), although gastrointestinal (p < 0.01), urinary (p < 0.01), and pupillomotor (p < 0.01) domains were more represented in the non-neurological symptoms group. This study confirms the importance of monitoring ANS symptoms as a possible complication of COVID-19 disease that may persist in the post-acute period.


Sign in / Sign up

Export Citation Format

Share Document